Search for drugs:
Typing the drug name to query
CILOSTAZOL
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- ADVERSE REACTIONS
- Postmarketing Experience
- The following adverse reactions have been identified during post-approval use of cilostazol tablets. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Cardiac disorders:
- Torsade de pointes and QTc prolongation in patients with cardiac disorders (e.g. complete atrioventricular block, heart failure; and bradyarrythmia), angina pectoris.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
18
24074
Other ADRs
7523
38374064
Odds Ratio = 3.814
Drug Property Information
ATC Code(s):
- B01AC23 - cilostazol
- B01AC - Platelet aggregation inhibitors excl. heparin
- B01A - ANTITHROMBOTIC AGENTS
- B01 - ANTITHROMBOTIC AGENTS
- B - BLOOD AND BLOOD FORMING ORGANS
Active Ingredient:CILOSTAZOL
Active Ingredient UNII:N7Z035406B
Drugbank ID:DB01166
PubChem Compound:2754
CTD ID:D000077407
PharmGKB:PA164746334
CAS Number:73963-72-1
Dosage Form(s):tablet
Route(s) Of Administrator:oral
Daily Dose:
- 200.0 mg/day B01AC23
Chemical Structure: 
SMILE Code:
O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2
O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2
Reference
1: An analysis of QTc prolongation with atypical antipsychotic medications and selective serotonin reuptake inhibitors using a large ECG record database.
[Park Sang-In,An Hyungmi,Kim Anhye,Jang In-Jin,Yu Kyung-Sang,Chung Jae-Yong]Expert Opin Drug Saf,2016 Aug;15(8):1013-9. PMID: 27276059
2: Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.
[Sanganalmath Santosh K,Barta Judit,Takeda Nobuakira,Kumamoto Hideo,Dhalla Naranjan S]Can J Physiol Pharmacol,2008 Apr;86(4):180-9. PMID: 18418427
3: Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome.
[Shimizu Wataru,Aiba Takeshi,Antzelevitch Charles]Curr Pharm Des,2005;11(12):1561-72. PMID: 15892662
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.